12:00 AM
Mar 20, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VEGF-2: Phase I/II

Researchers reported on a Phase I/II dose escalation study of VEGF-2 gene therapy in 30 patients with stable and refractory exertional angina who were not candidates for revascularization procedures. A total of 70 percent of patients had reductions of at least two angina classes after 12 weeks, and the...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >